Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
43
about 5.1 years
18+
1 site in CA
What this study is about
This trial is testing personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) together with HyperArc radiation treatment planning technology to see if it helps control tumors in people with head and neck cancer who can't have standard treatments. Researchers want to determine if using HyperArc and PULSAR will deliver higher doses of radiation, potentially leading to better tumor control with fewer side effects than smaller routine doses.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Best Practice
- 2.Participate in Functional Assessment of Cancer Therapy-Head & Neck
- 3.Participate in University of Washington Quality of Life Scale, Version 4
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Time to progression of the treated tumor target
Secondary: Disease progression free survival (PFS), Grade 3 or higher treatment-related toxicity, Incidence of adverse events (AE), Longitudinal patient reported outcomes on the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) Questionnaire, Longitudinal patient reported outcomes on the University of Washington Quality of Life (UW-QoL) Questionnaire, Overall survival (OS)
imaging, diagnostic, radiation
Oncology